Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

59.13USD
21 Aug 2018
Change (% chg)

$-0.30 (-0.50%)
Prev Close
$59.43
Open
$59.34
Day's High
$59.38
Day's Low
$59.13
Volume
2,747
Avg. Vol
106,886
52-wk High
$60.00
52-wk Low
$34.58

Latest Key Developments (Source: Significant Developments)

Cepi Awards $36 Million Contract To Profectus Biosciences And Emergent Biosolutions
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Emergent BioSolutions Inc ::CEPI AWARDS CONTRACT WORTH UP TO $36 MILLION TO PROFECTUS BIOSCIENCES AND EMERGENT BIOSOLUTIONS TO DEVELOP LASSA VIRUS VACCINE.COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS - AS PER CONTRACT, PROFECTUS WILL RECEIVE DEVELOPMENT FUNDING FROM CEPI FOR ADVANCING ITS LASSA VIRUS VACCINE.  Full Article

Emergent Biosolutions Inc Files For Potential Mixed Shelf Offering
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING.  Full Article

Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​
Monday, 26 Mar 2018 

March 26 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY.EMERGENT BIOSOLUTIONS INC - ‍APPOINTED RICHARD S. LINDAHL AS COMPANY'S NEW EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.EMERGENT BIOSOLUTIONS INC - PROMOTED ROBERT G. KRAMER SR. TO NEWLY-CREATED POSITION OF PRESIDENT AND CHIEF OPERATING OFFICER​.EMERGENT BIOSOLUTIONS - ‍LINDAHL MOST RECENTLY SERVED AS CFO AT CEB INC​.  Full Article

Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK.SEES FY 2017 REVENUE $555 MILLION TO $560 MILLION.SEES Q1 2018 REVENUE $145 MILLION TO $160 MILLION.SEES FY 2017 REVENUE UP 14 PERCENT.- FOR FULL YEAR 2017, ANTICIPATES CASH AND CASH EQUIVALENTS AT YEAR END OF ABOUT $180 MILLION.- SEES 2018 TOTAL REVENUES FROM $715 MILLION TO $755 MILLION.SEES 2018 ADJUSTED NET INCOME $110 MILLION TO $125 MILLION.- FULL YEAR 2017 ADJUSTED NET INCOME IS ANTICIPATED TO BE $92 TO $96 MILLION.- FOR FULL YEAR 2017, ANTICIPATES NET INCOME OF $80 TO $84 MILLION.SEES 2018 NET INCOME $95 MILLION TO $110 MILLION.FY2017 REVENUE VIEW $547.9 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $659.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Emergent Biosolutions Awarded Department Of National Defence Contract
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS AWARDED DEPARTMENT OF NATIONAL DEFENCE CONTRACT TO SUPPLY ANTHRASIL TO THE CANADIAN GOVERNMENT.HAS BEEN AWARDED CONTRACT BY DEPARTMENT OF NATIONAL DEFENCE VALUED AT ABOUT $8 MILLION TO DELIVER ANTHRASIL TO CANADIAN GOVERNMENT.  Full Article

Emergent Biosolutions reports third quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Emergent Biosolutions Inc :Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance.Q3 earnings per share $0.68.Q3 revenue $149.4 million versus I/B/E/S view $124.6 million.Q3 earnings per share view $0.41 -- Thomson Reuters I/B/E/S.Emergent Biosolutions Inc sees FY 2017 ‍total revenues $540 million to $560​ million.Emergent Biosolutions Inc sees ‍FY 2017 net income $70 million to $80​ million.Emergent Biosolutions Inc sees FY 2017 ‍adjusted net income $85 million to $95​ million.  Full Article

Emergent awarded BARDA contract for advanced development of NuThrax
Friday, 30 Sep 2016 

Emergent Biosolutions Inc : Awarded BARDA contract for advanced development and delivery of NuThrax, a next generation anthrax vaccine, valued at up to $1.6 billion . Contract includes options for an additional clinical study and post-marketing commitments valued at $48 million . Company anticipates that FDA could authorize NuThrax for emergency use as early as 2018 .Contract includes options for delivery of additional 7.5 million to 50 million doses of NuThrax, valued about $255 million to up to $1.4 billion.  Full Article

India steps up hunt for origin of mysterious brain-damaging virus

MUMBAI/KOCHI, May 28 India began a fresh round of tests to trace the origin of a rare brain-damaging virus that has killed 13 people, a health official said on Monday, as initial tests on animals suspected of carrying the Nipah virus showed no sign of the disease.